Eurogin · 2027

Agoris analysis · updated June 2026

Key takeaways

• Eurogin 2026: international multidisciplinary HPV congress, 18-21 March 2026 at the Austria Center Vienna (Vienna, Austria). Long-standing format: four full days of scientific sessions and industry partner exhibitions.
• 2025 edition (Porto, 16-19 March): 1,700+ delegates from 79 countries, 80+ scientific sessions, 616 oral presentations. European accreditation EACCME: 23 ECMEC credits for physicians.
• Organiser: Eurogin Scientific Society, founded in 1993 by Dr Joseph Monsonego (gynaecologist-oncologist, holding a dual position as Medical Director of the Institut Alfred Fournier and founder of the Institut du Col in Paris). Eurogin anticipated by 10 years the arrival of prophylactic HPV vaccines (Gardasil 2006, Cervarix 2007) and the shift towards primary HPV screening.
• The only genuinely multidisciplinary international congress on HPV: gynaecologists, oncologists, infectious-disease specialists, virologists, cytopathologists, ENT specialists (oropharyngeal cancers), proctologists, urologists, venereologists, epidemiologists, vaccinologists, and public health decision-makers. The Eurogin Roadmaps published in the International Journal of Cancer (Wiley) in 2010, 2011, 2012, 2014, 2015, 2017 give the congress a near-doctrinal status.
• Recent calendar: Bilbao 2023 (Euskalduna), Stockholm 2024, Porto 2025, Vienna 2026, Bologna 10-13 February 2027. Annual rotation across Europe's scientific capitals.

Who exhibits

Typical profile

The Eurogin exhibitor line-up reflects the three industrial pillars of the HPV field: prophylactic vaccines, molecular diagnostics (HR-HPV tests, genotyping, self-sampling), and AI-assisted cytopathology/colposcopy solutions. Added to these are scientific publishers, partner learned societies, and stakeholders in Europe's organised screening programmes.

Notable exhibitors

Confirmed presence for 2026: Fujirebio (booth B10).

Exhibitors historically expected at Eurogin:

• HPV vaccines: MSD (Gardasil 9), GSK (Cervarix), Sanofi Pasteur.
• Molecular HPV diagnostics: Roche Diagnostics (cobas HPV), Hologic (Aptima HPV, ThinPrep), Becton Dickinson (BD Onclarity), Abbott Molecular (Alinity m HPV), Qiagen (digene HC2), Seegene, CC Diagnostics, Fujirebio.
• Cytopathology and colposcopy equipment manufacturers: long-standing pioneers of cervical screening, AI suppliers for diagnostic support.

The final 2026 exhibitor list is published on the official Eurogin website as registrations come in.

Quality of the visitor base

• 1,700+ delegates expected, an audience that is 100% health and HPV-industry professionals.
• 79 countries represented in 2025: Eurogin is the field's global meeting point, not a regional congress.
• A rare multidisciplinary mix: a single venue to address the office-based gynaecologist, the head of a hospital cytopathology department, the ENT oncologist, the WHO epidemiologist and the public health decision-maker all at once.
• Eurogin Grants: a bursary programme for researchers from low- and middle-income countries (LMICs), aligned with the WHO cervical cancer elimination strategy (targeting sub-Saharan Africa and South-East Asia).

Activities & community

Conference programme

The 2026 scientific programme covers the entire HPV spectrum:

• HPV epidemiology and surveillance of circulating genotypes.
• Primary HPV screening vs cytology, extended genotyping, HPV+ triage (cytology, biomarkers, methylation).
• Artificial intelligence applied to cytopathology and colposcopy: flagship sessions of the 2026 edition.
• Prophylactic vaccination: the single-dose schedule, adult catch-up, male vaccination.
• WHO cervical cancer elimination strategy by 2030: the 90-70-90 target (90% vaccinated, 70% screened, 90% treated).
• HPV-induced cancers beyond the cervix: anal, oropharyngeal, vulvar, vaginal, penile.
• Management of HSIL/CIN, immunotherapy of precancerous lesions, vaginal microbiome, STI co-infections.
• Anal cancer screening in HIV+ MSM, male HPV health, vaginal self-sampling as a lever for including under-screened populations.

Congress presidents for 2026: announced by Eurogin, to be confirmed on the final programme.

Awards & accolades

Award-winning oral and poster communication sessions, the classic structure of major scientific congresses. The Eurogin Roadmaps published in the International Journal of Cancer constitute the congress's most visible editorial output, and draw part of their substance from presentations selected on site.

Satellite events

Industry symposia (vaccines, molecular diagnostics) running alongside the main scientific programme. Partner sessions with national and international learned societies (EUROGIN has historical ties to the IPVS, ESGO and EFC).

Community & networks

The IARC (International Agency for Research on Cancer, Lyon) is a regular scientific contributor to Eurogin (shared publications). At Eurogin 2026, Iacopo Baussano (IARC) presents the updated European recommendations on cervical screening.

On site: what you need to know

The congress is held at the Austria Center Vienna, Austria's main congress centre, located in Vienna. Access to UN-Donaustadt is via line U1 of the Vienna underground, 25 minutes from Vienna-Schwechat Airport. Capacity for several thousand delegates in plenary, the standard configuration of major international medical congresses.

Congress-specific details:

• Dates: 18 to 21 March 2026, four full days.
• Badge: named registration is mandatory via the official platform, with professional proof required for reduced rates (resident, student, allied health professional).
• Working language: English (the congress's official language).
• Training credits: long-standing EACCME accreditation (23 ECMEC credits in 2025), to be confirmed for 2026.

What it costs to exhibit

Medical B2B registrations are centralised via the Euromedicom platform (order.euromedicom.com), with the classic early bird / standard / on-site tier structure and differentiated rate scales:

• Health professionals (physicians, researchers)
• Industry (vaccines, diagnostics, equipment manufacturers)
• Students and allied health professionals

The final 2026 rate scale is to be confirmed on the Euromedicom portal. As a guide, based on previous editions: 500 to €900 excl. VAT for health professionals, 800 to €1,200 excl. VAT for industry.

Exhibitor stand rates for industrial exhibitors (sponsorship, satellite symposia, booth spaces): quotation on request from the Eurogin / Euromedicom secretariat.

Preparing your visit

For the industrial exhibitor

• 9 months out: make contact with the Eurogin secretariat to book a booth and satellite symposium (symposium slots go quickly).
• 6 months out: choose the format (booth only, booth + symposium, cross-cutting sponsorship), confirm the sponsorship package.
• 3 months out: scientific messaging aligned with the 2026 flagship sessions (AI in cytopathology, self-sampling, male vaccination).
• 6 weeks out: team logistics, accommodation in Vienna (book early, a tourist city in March).
• 1 week out: brief the team on the multidisciplinary audience (different vocabulary and arguments depending on whether you are addressing an office-based gynaecologist, a hospital cytopathologist or a public health epidemiologist).

For the delegate

• Early bird registration is strongly recommended (significant saving versus the on-site rate).
• Vienna in March: cool weather, bring mid-season clothing.
• Accommodation: the UN-Donaustadt district (immediately next to the Austria Center) or the historic city centre (35 min on the U1).
• Pre-select your sessions from the official programme: 80+ sessions run in parallel, and covering everything is impossible without a visit plan.

Policy & CSR initiatives

Eurogin carries a strong public health dimension through two structuring pillars:

• WHO alignment with the cervical cancer elimination strategy for 2030 (the 90-70-90 target), which shapes a significant part of the scientific programme.
• Eurogin Grants: a bursary scheme for researchers from low- and middle-income countries (LMICs), with an operational focus on sub-Saharan Africa and South-East Asia, the regions where cervical cancer mortality remains highest.

The congress also gives growing prominence to vaginal self-sampling as a lever for including under-screened populations, and to the HPV health of long-overlooked groups (HIV+ MSM, men, migrant populations).

How the trade show has evolved

Trajectory analysis

Eurogin has positioned itself since 1993 as the world's reference HPV congress, on a trajectory that faithfully follows the field's major inflection points: anticipation of prophylactic vaccines in the 2000s, the shift to primary HPV screening in the 2010s, and the integration of AI in cytopathology and colposcopy around 2020. The annual rotation across Europe's scientific capitals (Bilbao, Stockholm, Porto, Vienna, Bologna) ensures constant renewal of the regional audience while maintaining a stable international core of 1,700+ delegates representing close to 80 countries. For 2026, the editorial focus narrows to three subjects: AI applied to screening, self-sampling as a tool for inclusion, and operationalising the WHO 90-70-90 strategy in countries with a high cervical cancer burden.

Unless otherwise stated, all factual data in this listing comes from the organiser's official website (eurogin.com).